Imatinib treatment
Neoadjuvant imatinib treatment and laparoscopic anus preserving surgery for a large gastrointestinal stromal tumor of the rectum
... Several approaches exist for resection of rectal GIST, but the principle of surgery is complete resection with an intact pseudo-capsule [10, 11]. Local resection, such as transanal, trans-sacral, or transvaginal, may be ...
5
Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
... adjuvant imatinib treat- ment based on available evidence, some agencies rec- ommend adjuvant imatinib ...adjuvant imatinib treatment after resection for primary GIST for at least 12 months in ...
12
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
... adjuvant treatment strategies were assessed only in patients who had a high-risk (>50% risk of recurrence according to Miettinen’s criteria) GIST resected and who had a registration date starting from March ...
8
Update on imatinib for gastrointestinal stromal tumors: duration of treatment
... of imatinib failure is acquired secondary resistance mutations or ...to imatinib in patients with advanced GIST can be delayed, the French Sarcoma Group designed a Phase III trial (BFR-14) that randomized ...
13
Targeted treatment of chronic myeloid leukemia: role of imatinib
... Adverse events (Table 2) with imatinib are generally mild, with rare grade 3 or 4 toxicities. Myelosuppression (neutropenia, thrombocytopenia, anemia) is the most frequent adverse event (16.7% in the IRIS study). ...
10
Original Article Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines
... the Imatinib resistance that, if the disease progress, the patients of 400 mg/d dose group were distributed to the high dose group of 800 mg/d [5, ...mg/d Imatinib treatment group was rather ...
8
Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
... of imatinib has turned chronic myeloid leukaemia (CML) into a chronic illness due to the dramatic improvement in ...to imatinib may hamper the therapeutic outcomes and result in increased medical ...
8
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
... to imatinib treatment results in signif- icantly lower response rates in patients with ...to imatinib treatment was analyzed in 169 patients with CML during a 90-day period and corre- lated ...
10
Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China
... of imatinib in F/P fusion gene positive CEL has since been confirmed in numerous studies, and imatinib is recommended as a clear first-line therapy in patients with F/P-positive CEL ...daily imatinib ...
8
<p>Gastrointestinal Stromal Tumors of the Small Intestine: Progress in Diagnosis and Treatment Research</p>
... prolonged treatment that may lead to tumor necrosis, cystic changes, rupture, and hemorrhage Kang et ...neoadjuvant imatinib treatment could be considered with high karyokinesis exponents or large ...
13
Original Article Human umbilical cord mesenchymal stem cells restore imatinib and doxorubicin sensitivity in drug-resistant chronic myeloid leukemia cells
... K562-derived imatinib-resistant cell line. Imatinib-resistant K562 cells were generated from sequential imatinib treatment of K562 ...hUC-MSCs, imatinib-sensitive and ...
6
Low dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
... from imatinib treatment, especially those with HRCT of the lung characterized by ground-glass (Figure ...of imatinib on established fibrosis; longer treatment should also be taken into ...
10
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies
... in imatinib-resistant CML LAMA84 cells, both expression and activity of CK2 are up-regulated as compared to imatinib-sensitive cells and that CK2 co-operates with Bcr-Abl to maintain the CML ...and ...
15
The pharmacogenetics of imatinib
... [35,36]. For example, the Arg61Cys, Cys88Arg and Gly401Ser amino acid replacements resulting from the corresponding genetic polymorphisms were shown to aff ect the transport of hOCT1 substrates [30]. Bazeos et al. [37] ...
8
Clinical and Biological Features at Diagnosis in 40 Children With Chronic Myeloid Leukemia
... Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase..[r] ...
6
Resistant mutations in CML and Ph<sup>+</sup>ALL – role of ponatinib
... versus Imatinib in Chronic Myeloid Leukemia; FGFR, fibroblast growth factor receptor; FLT, FMS-like tyrosine kinase; FYN, fyn kinase; KIT, kinase receptor; LVEF, left ventricular ejection fraction; LYN, Lck/yes ...
12
Imatinib Preoperative Treatment for Gastrointestinal Stromal Tumors Clinical Analysis of 16 Cases
... with imatinib for unresectable/potentially resectable gaster and duodenum gastrointestinal stromal tumor ...received imatinib as preoperative therapy at the Affiliated Hospital of Inner Mongolia Medical ...
6
A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
... musculoskeletal pain. No grade 3 or 4 episodes were recorded. A similar pattern, albeit at lower frequency, was also observed for other common TKI adverse events, summarised in the Supplementary Table. Interestingly, all ...
27
Severe paraneoplastic hypoglycemia secondary to a gastrointestinal stromal tumour masquerading as a stroke
... Optimal management of NICTH includes hypoglycae- mia symptom control, surgical removal of the primary tumour if amenable to surgical resection, thereby target- ing the source of IGF2 excess ectopic production. However, ...
6
Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
... that imatinib dose escalation appears to induce sustained responses in a subset of patients with cytogenetic failure or acquired cytogenetic ...HD imatinib does not significantly improve patient outcomes ...
8